Elucidata Stock

Elucidata delivers ML-ready biomedical molecular data that is curated to accelerate drug discovery.

Sign up today and learn more about Elucidata Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Elucidata Stock

Elucidata's proprietary SaaS platform, Polly, transforms drug discovery- one curated dataset at a time. Polly delivers ML-ready biomedical molecular data for accelerated drug discovery. Hosting a rich repository of more than 230,000 multi-omic datasets, Polly curates data semi-automatically, with over 50,000 datasets added each month. The company equips data-driven drug discovery teams with a code-first SaaS platform that integrates proprietary and public biomedical molecular data for ML applications. Inspired by the FAIR guidelines described by the NIH, Polly's Data Lakes allow exclusive access to curated multi-omics data that is ready for ML workflows. Polly offers 10x faster identification of therapeutic assets with high odds of success in the clinic. It has enabled the detection of multiple validated drug targets across immunology, oncology, and metabolomic disorders. Polly supports discovery programs at Pfizer, Agios Pharmaceuticals, Genentech, and Yale and has 35+ research partners from premier biopharma companies and research labs.

Funding History

June 2018$1.7M
July 2020$880K
January 2021$5.0M
September 2022$16.0M


Investor and Advisor

Venkat Tadanki

CEO & President

Abhishek Jha


Raghav Gupta


Swetabh Pathak

Scientific Advisor

Avi Ma'ayan

Scientific Advisory Board and Co-Founder

Richard Kibbey


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: